Three barriers to innovative diagnostics

Nature Biotechnology

Volumn 24, Issue 8, 2006, Pages 917-918

  Billings, Paul R ^a  

^a LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD HOSPITALIZATION; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH HAZARD; HEALTH SERVICE; HUMAN; MEDICAL CARE; MEDICARE; NOTE; PATIENT CARE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UNITED STATES;

COST-BENEFIT ANALYSIS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; ENTREPRENEURSHIP; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 33747051439     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0806-917     Document Type: Note

References (4)

1. The Lewin Group. The Value of Diagnostics: Innovation, Adoption and Diffusion into Health Care. The Lewing Group. Washington, DC. July, 2005. http://www.advamed.org/publicdocs/thevalueofdiagnostics.pdf.
2. Haga, B. & Burke, W. Using pharmacogenetics to improve drug safety and efficacy. JAMA 2004; 291, 2869-2871.
3. Stoler, M. & Schiffman, M., for the Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285, 1500-1505.
4. Billings P. Genetic nondiscrimination. Nature Genetics 2005; 37, 559-560.